Cargando…

Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer

BACKGROUND: Metabolomics studies to date have described widespread metabolic reprogramming events during the development of non-squamous non-small cell lung cancer (NSCLC). Extending far beyond the Warburg effect, not only is carbohydrate metabolism affected, but also metabolism of amino acids, cofa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ivanina Foureau, Anna V., Sha, Wei, Foureau, David M., Symanowski, James T., Farhangfar, Carol J., Mileham, Kathryn F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830272/ https://www.ncbi.nlm.nih.gov/pubmed/36636422 http://dx.doi.org/10.21037/tlcr-22-377

Ejemplares similares

Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
por: Eisner, Joel R., et al.
Publicado: (2023)

Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer
por: Eisner, Joel R., et al.
Publicado: (2022)

Unlocking the Diversity of Alkaloids in Catharanthus roseus: Nuclear Localization Suggests Metabolic Channeling in Secondary Metabolism
por: Stavrinides, Anna, et al.
Publicado: (2015)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

BCKDK alters the metabolism of non-small cell lung cancer
por: Wang, Yanhui, et al.
Publicado: (2021)

The Purinergic Landscape of Non-Small Cell Lung Cancer
por: Janho dit Hreich, Serena, et al.
Publicado: (2022)

Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma
por: Jagosky, Megan H., et al.
Publicado: (2022)

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review
por: Liu, Yu, et al.
Publicado: (2021)

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer
por: Pécuchet, Nicolas, et al.
Publicado: (2015)

Tumor immunity landscape in non-small cell lung cancer
por: Yu, Xiaoqing, et al.
Publicado: (2018)

Resectable non-small cell lung cancer: an evolving landscape
por: Loh, Jerold, et al.
Publicado: (2022)

Changing the landscape of non-small cell lung cancer disparities
por: Odera, Joab O., et al.
Publicado: (2021)

Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review
por: Zhu, Xiaokuan, et al.
Publicado: (2022)

Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer
por: Li, Jianqiang, et al.
Publicado: (2020)

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
por: Foureau, David M., et al.
Publicado: (2020)

The Circular RNA Landscape of Non-Small Cell Lung Cancer Cells
por: Van Der Steen, Nele, et al.
Publicado: (2020)

Current treatment landscape for oligometastatic non-small cell lung cancer
por: Garde-Noguera, Javier, et al.
Publicado: (2022)

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer
por: Yagishita, Shigehiro, et al.
Publicado: (2015)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
por: Huemer, Florian, et al.
Publicado: (2018)

Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Kim, Jung Han, et al.
Publicado: (2018)

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
por: Ricciardi, Serena, et al.
Publicado: (2009)

Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
por: Melosky, Barbara
Publicado: (2014)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2015)

Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer
por: Zhao, Jiangang, et al.
Publicado: (2020)

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
por: Yuan, Min, et al.
Publicado: (2019)

Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
por: Lim, Sun Min, et al.
Publicado: (2020)

Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer
por: Wei, Xue‐Wu, et al.
Publicado: (2020)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

The Fusion Gene Landscape in Taiwanese Patients with Non-Small Cell Lung Cancer
por: Chang, Ya-Sian, et al.
Publicado: (2021)

The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis
por: Zhang, Qi, et al.
Publicado: (2022)

Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases
por: Huang, Richard S P, et al.
Publicado: (2022)

A landscape of response to drug combinations in non-small cell lung cancer
por: Nair, Nishanth Ulhas, et al.
Publicado: (2023)

When perception reflects reality: Non‐native grass invasion alters small mammal risk landscapes and survival
por: Ceradini, Joseph P., et al.
Publicado: (2017)

Alterations of lung microbiota in patients with non-small cell lung cancer
por: Zeng, Wen, et al.
Publicado: (2022)

FGFR1–4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer
por: Moes-Sosnowska, Joanna, et al.
Publicado: (2022)

Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
por: Melosky, Barbara
Publicado: (2017)

Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
por: Fujimoto, Daichi, et al.
Publicado: (2023)

The non-coding landscape of head and neck squamous cell carcinoma
por: Zou, Angela E., et al.
Publicado: (2016)

Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
por: Rothwell, Ben, et al.
Publicado: (2020)

Altered expression of ACOX2 in non-small cell lung cancer
por: Sui, Jane S. Y., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ap8dibld46nu3m7tl2m68d9kf